{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:09:56Z","timestamp":1790784596243,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.biopha.2016.04.019","type":"journal-article","created":{"date-parts":[[2016,4,26]],"date-time":"2016-04-26T14:47:35Z","timestamp":1461682055000},"page":"288-294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation"],"prefix":"10.1016","volume":"81","author":[{"given":"Xuejiao","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinghong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luoting","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2016.04.019_bib0005","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/nrd2974","article-title":"Protein methyltransferases as a target class for drug discovery","volume":"8","author":"Copeland","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2016.04.019_bib0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1747-0285.2011.01135.x","article-title":"Chemogenetic analysis of human protein methyltransferases","volume":"78","author":"Richon","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.biopha.2016.04.019_bib0015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2016.04.019_bib0020","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1158\/1078-0432.CCR-10-2156","article-title":"Aberrations of EZH2 in cancer","volume":"17","author":"Chase","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2016.04.019_bib0025","doi-asserted-by":"crossref","first-page":"11606","DOI":"10.1073\/pnas.1933744100","article-title":"EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells","volume":"100","author":"Kleer","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2016.04.019_bib0030","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2016.04.019_bib0035","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/onc.2008.433","article-title":"Downregulation of EZH2 decreases growth of estr ogen receptor-negative invasive breast carcinoma and requires BRCA1","volume":"28","author":"Gonzalez","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2016.04.019_bib0040","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.25679","article-title":"Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis","volume":"56","author":"Au","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2016.04.019_bib0045","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/cdd.2009.162","article-title":"Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression","volume":"17","author":"Wu","year":"2010","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2016.04.019_bib0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2016.04.019_bib0055","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2016.04.019_bib0060","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.1116418109","article-title":"Mutation of A677 in histone methyltransferase EZH2 inhuman B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27(H3K27)","volume":"109","author":"McCabe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2016.04.019_bib0065","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/leu.2010.311","article-title":"EZH2 Y641 mutations in follicular lymphoma","volume":"25","author":"B\u00f6d\u00f6r","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2016.04.019_bib0070","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation","volume":"117","author":"Yap","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2016.04.019_bib0075","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","article-title":"Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on hist one H3(H3K27) in human B-cell lymphomas","volume":"107","author":"Sneeringer","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2016.04.019_bib0080","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/j.febslet.2011.08.018","article-title":"The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methyl ation states","volume":"585","author":"Wigle","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2016.04.019_bib0085","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/cb400133j","article-title":"An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1","volume":"8","author":"Konze","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.biopha.2016.04.019_bib0090","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nchembio.1084","article-title":"A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells","volume":"8","author":"Knutson","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.biopha.2016.04.019_bib0095","doi-asserted-by":"crossref","first-page":"21360","DOI":"10.1073\/pnas.1210371110","article-title":"Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation","volume":"109","author":"Qi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2016.04.019_bib0100","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/nrd2974","article-title":"Protein methyltransferases as a target class for drug discovery","volume":"8","author":"Copeland","year":"2009","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.biopha.2016.04.019_bib0105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","article-title":"Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor","volume":"20","author":"Daigle","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2016.04.019_bib0110","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.molcel.2007.01.017","article-title":"Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase","volume":"25","author":"Kubicek","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2016.04.019_bib0115","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1021\/jm3018332","article-title":"Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors","volume":"56","author":"Liu","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2016.04.019_bib0120","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature12751","article-title":"Chromatin proteins and modifications as drug targets","volume":"502","author":"Helin","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2016.04.019_bib0125","doi-asserted-by":"crossref","first-page":"11606","DOI":"10.1073\/pnas.1933744100","article-title":"EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells","volume":"100","author":"Kleer","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2016.04.019_bib0130","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2016.04.019_bib0135","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1158\/1535-7163.MCT-09-0013","article-title":"DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation","volume":"8","author":"Miranda","year":"2009","journal-title":"Mol. Cancer Ther."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332215304285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332215304285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:29:43Z","timestamp":1788877783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332215304285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":27,"alternative-id":["S0753332215304285"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2016.04.019","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2016.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}